{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T03:13:13Z","timestamp":1785640393207,"version":"3.56.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["apjon.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Oncology Nursing"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.apjon.2023.100280","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T21:23:09Z","timestamp":1690838589000},"page":"100280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S1","title":["The role of pharmacists in multimodal cancer cachexia care"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0944-7290","authenticated-orcid":false,"given":"Hironori","family":"Fujii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunami","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apjon.2023.100280_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apjon.2023.100280_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s13539-012-0087-1","article-title":"Cancer cachexia: impact, mechanisms and emerging treatments","volume":"4","author":"Vaughan","year":"2013","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.apjon.2023.100280_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jpainsymman.2012.06.020","article-title":"Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis","volume":"46","author":"Oberholzer","year":"2013","journal-title":"J\u00a0Pain Symptom Manag"},{"key":"10.1016\/j.apjon.2023.100280_bib4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.21873\/anticanres.16188","article-title":"The latest treatments for cancer cachexia: an Overview","volume":"43","author":"Watanabe","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.apjon.2023.100280_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2020.03.003","article-title":"Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors","volume":"143","author":"Roch","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.apjon.2023.100280_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3892\/mco.2022.2524","article-title":"Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer","volume":"16","author":"Fujii","year":"2022","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.apjon.2023.100280_bib7","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.21873\/anticanres.14734","article-title":"Cancer cachexia reduces the efficacy of nivolumab treatment in patients with advanced gastric cancer","volume":"40","author":"Fujii","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.apjon.2023.100280_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","article-title":"ESPEN guidelines on nutrition in cancer patients","volume":"36","author":"Arends","year":"2017","journal-title":"Clin Nutr"},{"key":"10.1016\/j.apjon.2023.100280_bib9","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.clnu.2016.07.001","article-title":"ESPEN guideline on ethical aspects of artificial nutrition and hydration","volume":"35","author":"Bozzetti","year":"2016","journal-title":"Clin Nutr"},{"key":"10.1016\/j.apjon.2023.100280_bib10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1365-2753.2011.01665.x","article-title":"Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic","volume":"18","author":"Iihara","year":"2012","journal-title":"J\u00a0Eval Clin Pract"},{"key":"10.1016\/j.apjon.2023.100280_bib11","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cncr.31128","article-title":"Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)","volume":"124","author":"Katakami","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.apjon.2023.100280_bib12","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1002\/cncr.32406","article-title":"A\u00a0multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia","volume":"125","author":"Hamauchi","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.apjon.2023.100280_bib13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apjon.2023.100280_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","article-title":"Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial","volume":"14","author":"Dobs","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apjon.2023.100280_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/030089161309900218","article-title":"Comparison of three different treatment modalities in the management of cancer cachexia","volume":"99","author":"Kanat","year":"2013","journal-title":"Tumori"},{"key":"10.1016\/j.apjon.2023.100280_bib16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1634\/theoncologist.2009-0153","article-title":"Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia","volume":"15","author":"Mantovani","year":"2010","journal-title":"Oncol"},{"key":"10.1016\/j.apjon.2023.100280_bib17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clnu.2011.10.005","article-title":"Randomized phase III clinical trial of a combined treatment with carnitine+ celecoxib\u00b1megestrol acetate for patients with cancer-related anorexia\/cachexia syndrome","volume":"31","author":"Madeddu","year":"2012","journal-title":"Clin Nutr"},{"key":"10.1016\/j.apjon.2023.100280_bib18","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1186\/s12885-018-5080-4","article-title":"Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials","volume":"18","author":"Advani","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.apjon.2023.100280_bib19","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1210\/me.2008-0160","article-title":"Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways","volume":"22","author":"Narayanan","year":"2008","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.apjon.2023.100280_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13539-014-0159-5","article-title":"Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile","volume":"5","author":"Pietra","year":"2014","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.apjon.2023.100280_bib21","first-page":"199","article-title":"Clinical results in cachexia therapeutics","volume":"19","author":"Crawford","year":"2016","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.apjon.2023.100280_bib22","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1210\/jc.2004-1788","article-title":"Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia","volume":"90","author":"Garcia","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.apjon.2023.100280_bib23","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1200\/JCO.2012.44.4661","article-title":"Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer","volume":"31","author":"Yennurajalingam","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.apjon.2023.100280_bib24","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1200\/JCO.2013.54.3926","article-title":"Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial","volume":"32","author":"Paulsen","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.apjon.2023.100280_bib25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jpainsymman.2016.01.015","article-title":"Predictors of responses to corticosteroids for cancer-related fatigue in advanced cancer patients: a multicenter, prospective, observational study","volume":"52","author":"Matsuo","year":"2016","journal-title":"J\u00a0Pain Symptom Manag"},{"key":"10.1016\/j.apjon.2023.100280_bib26","doi-asserted-by":"crossref","first-page":"8662","DOI":"10.1007\/s00330-021-07899-6","article-title":"Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer","volume":"31","author":"Salinas-Miranda","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.apjon.2023.100280_bib27","first-page":"197","article-title":"Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study","volume":"31","author":"Suzuki","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.apjon.2023.100280_bib28","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/1759-7714.14881","article-title":"Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors","volume":"14","author":"Matsuo","year":"2023","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.apjon.2023.100280_bib29","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/cancers15041076","article-title":"Effect of cancer-related cachexia and associated changes in nutritional status, inflammatory status, and muscle mass on immunotherapy efficacy and survival in patients with advanced non-small cell lung cancer","volume":"15","author":"Madeddu","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.apjon.2023.100280_bib30","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.urolonc.2022.07.018","article-title":"Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma","volume":"40","author":"Aslan","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.apjon.2023.100280_bib31","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.1038\/s41598-022-11736-1","article-title":"Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy","volume":"12","author":"Goh","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.apjon.2023.100280_bib32","first-page":"4373","article-title":"Determining the prevalence and severity of cancer cachexia in advanced non-small cell lung cancer and its relationship with chemotherapy outcomes","volume":"28","author":"White","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.apjon.2023.100280_bib33","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3390\/biomedicines11030905","article-title":"Chemotherapy-induced molecular changes in skeletal muscle","volume":"11","author":"Pedrosa","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.apjon.2023.100280_bib34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: understanding the molecular basis","volume":"14","author":"Argil\u00e9s","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apjon.2023.100280_bib35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/jcsm.12391","article-title":"Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study","volume":"10","author":"da Rocha","year":"2019","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.apjon.2023.100280_bib36","first-page":"5271","article-title":"Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma","volume":"28","author":"Mitsunaga","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.apjon.2023.100280_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40780-022-00239-w","article-title":"Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy","volume":"8","author":"Fujii","year":"2022","journal-title":"J\u00a0Pharm Health Care Sci"},{"key":"10.1016\/j.apjon.2023.100280_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","article-title":"Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan society of clinical oncology clinical practice guidelines for antiemesis","volume":"26","author":"Aogi","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.apjon.2023.100280_bib39","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.apjon.2023.100280_bib40","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1592\/phco.22.11.841.33629","article-title":"Olanzapine-associated diabetes mellitus","volume":"22","author":"Koller","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.apjon.2023.100280_bib41","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.4088\/JCP.v64n1206","article-title":"Olanzapine induces insulin resistance: results from a prospective study","volume":"64","author":"Ebenbichler","year":"2003","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.apjon.2023.100280_bib42","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.22.01997","article-title":"Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer","volume":"41","author":"Sandhya","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.apjon.2023.100280_bib43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00280-015-2767-y","article-title":"Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis","volume":"76","author":"Matsuda","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.apjon.2023.100280_bib44","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.21873\/anticanres.12995","article-title":"Improvement of dysgeusia by polaprezinc, a zinc-L-carnosine, in outpatients receiving cancer chemotherapy","volume":"38","author":"Fujii","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.apjon.2023.100280_bib45","first-page":"141","article-title":"Impact of taste\/smell disturbances on dietary intakes and cachexia-related quality of life in patients with advanced cancer","volume":"31","author":"Hiroyuki","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.apjon.2023.100280_bib46","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.apjon.2023.100280_bib47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40261-019-00882-6","article-title":"Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial","volume":"40","author":"Salehifar","year":"2020","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.apjon.2023.100280_bib48","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/annonc\/mdu085","article-title":"Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force","volume":"25","author":"Aapro","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apjon.2023.100280_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2023.1063279","article-title":"Effect of combined therapies including nutrition and physical exercise in advanced cancer patients: a pooled analysis","volume":"10","author":"Storck","year":"2023","journal-title":"Front Nutr"},{"key":"10.1016\/j.apjon.2023.100280_bib50","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s10147-023-02300-6","article-title":"Health care professionals' experiences of dealing with cancer cachexia","volume":"28","author":"Ellis","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.apjon.2023.100280_bib51","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1002\/jcsm.13105","article-title":"Identification and management of cancer cachexia in patients: assessment of healthcare providers' knowledge and practice gaps","volume":"13","author":"Baracos","year":"2022","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.apjon.2023.100280_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjon.2022.100075","article-title":"Factors affecting the assessment of cancer cachexia by nurses caring for patients with advanced cancer undergoing chemotherapy: a cross-sectional survey","volume":"9","author":"Sato","year":"2022","journal-title":"Asia Pac J Oncol Nurs"},{"key":"10.1016\/j.apjon.2023.100280_bib53","article-title":"Nurses' knowledge in relation to the anorexia-cachexia syndrome in cancer patients: a cross-national comparison in two European countries","volume":"7","author":"Socratous","year":"2021","journal-title":"SAGE Open Nurs"},{"key":"10.1016\/j.apjon.2023.100280_bib54","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1002\/cam4.5206","article-title":"Efficacy and safety of anamorelin in patients with cancer cachexia: post-hoc subgroup analyses of a placebo-controlled study","volume":"12","author":"Takayama","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.apjon.2023.100280_bib55","article-title":"Impact of the extent of weight loss before administration on the efficacy of anamorelin in advanced pancreatic cancer patients with cachexia","author":"Takeda","year":"2022","journal-title":"Intern Med"}],"container-title":["Asia-Pacific Journal of Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2347562523000987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2347562523000987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:06:46Z","timestamp":1762423606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2347562523000987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":55,"alternative-id":["S2347562523000987"],"URL":"https:\/\/doi.org\/10.1016\/j.apjon.2023.100280","relation":{},"ISSN":["2347-5625"],"issn-type":[{"value":"2347-5625","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of pharmacists in multimodal cancer cachexia care","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjon.2023.100280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc. on behalf of Asian Oncology Nursing Society.","name":"copyright","label":"Copyright"}],"article-number":"100280"}}